期刊文献+

The differential effects of integrase strand transfer inhibitors and efavirenz on neuropsychiatric conditions and brain imaging in HIV-positive men who have sex with men

原文传递
导出
摘要 Integrase strand transfer inhibitors(INSTIs)have emerged as the first‐line choice for treating human immunodeficiency virus(HIV)infection due to their superior efficacy and safety.However,the impact of INSTIs on the development of neuropsychiatric conditions in people living with HIV(PLWH)is not fully understood due to limited data.In this study,we conducted a cross‐sectional examination of PLWH receiving antiretroviral therapy,with a specific focus on HIV‐positive men who have sex with men(MSM)on INSTI‐based regimens(n=61)and efavirenz(EFV)‐based regimens(n=28).Participants underwent comprehensive neuropsychiatric evaluations and multimodal magnetic resonance imaging(MRI)scans,including T1‐weighted images and resting‐state functional MRI.Compared to the EFV group,the INSTI group exhibited primarily reduced gray matter volume(GMV)in the right superior parietal gyrus,higher regional homogeneity(ReHo)in the left postcentral gyrus,lower ReHo in the right orbital part of the inferior frontal gyrus,and increased voxel‐wise functional connectivity for the seed region in the left inferior temporal gyrus with clusters in the right cuneus.Furthermore,the analysis revealed a main effect of antiretroviral drugs on GMV changes,but no main effect of neuropsychiatric disorders or their interaction.The repeated analysis of participants who did not switch regimens confirmed the GMV changes in the INSTI group,validating the initial findings.Our study demonstrated gray matter atrophy and functional brain changes in PLWH on INSTI‐based regimens compared to those on EFV‐based regimens.These neuroimaging results provide valuable insights into the characteristics of brain network modifications in PLWH receiving INSTI‐based regimens。
出处 《Biosafety and Health》 CAS CSCD 2024年第4期216-224,共9页 生物安全与健康(英文)
基金 supported by the National Natural Science Foundation of China(82072271,82241072,82072294) the National Key Research and Development Program of China(2021YFC2501402,2021YFC0122601) the Beijing Natural Science Foundation(7222095,7222091) the Peak Talent Program of Beijing Hospital Authority(DFL20191701) the Capital’s Funds for Health Improvement and Research(2022-1-1151) the Research and Translational Application of Clinical Characteristic Diagnostic and Treatment Techniques in Capital City(Z221100007422055) the Beijing Research Center for Respiratory Infectious Diseases(BJRID2024-001) the Beijing Hospitals Authority Innovation Studio of Young Staff Funding Support(2021037) the High-level Public Health Technical Personnel Construction Project(2022-1-007) the High-level Public Health Specialized Talents Project of Beijing Municipal Health commission(2022-02-20) the Beijing Key Laboratory for HIV/AIDS Research(BZ0089).
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部